Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Company Deals

Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million

Fineline Cube Jul 8, 2026
Company Deals

MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001

Fineline Cube Jul 8, 2026
Company Deals

Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China

Fineline Cube Jul 8, 2026
Company Deals

Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development

Fineline Cube Jul 7, 2026
Policy / Regulatory

China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List

Fineline Cube Jul 8, 2026
Company Drug

LTZ Therapeutics Secures FDA IND Approval for LTZ-232, First-in-Class Myeloid Engager Targeting EpCAM-High Solid Tumors

Fineline Cube Jul 8, 2026
Company Drug

Shanghai Stexo Biotechnology Secures NMPA Clinical Approval for STX11101 Extracellular Vesicle Therapy in Acute Liver Failure

Fineline Cube Jul 8, 2026
Company Deals

Fosun Pharma to Take Henlius Private in Deal Valued at HKD 5.407 Billion

Fineline Cube Jun 25, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced plans to take...

Company Drug

Shanghai Haihe Pharmaceutical’s Glumetinib Earns Marketing Approval in Japan for NSCLC Treatment

Fineline Cube Jun 25, 2024

Shanghai Haihe Pharmaceutical Co., Ltd, a Chinese pharmaceutical company, has announced that it has received...

Company Deals

Sun Yat-sen University and KingMed Diagnostics Collaborate on Talent Development and Research

Fineline Cube Jun 25, 2024

On June 20, 2024, the School of Public Health (Shenzhen) of Sun Yat-sen University and...

Company Deals

AnDiConBio Secures Over RMB 200 Million in Series A Financing to Advance Respiratory and Pain Therapies

Fineline Cube Jun 25, 2024

AnDiConBio, a Zhejiang-based innovative pharmaceutical company specializing in respiratory infections and pain management, has reportedly...

Company Drug

Haisco Pharmaceutical Gets NMPA Green Light for Cofrogliptin to Treat Type 2 Diabetes

Fineline Cube Jun 25, 2024

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received marketing approval...

Company Drug

Gan & Lee Pharmaceuticals’ GZR18 Outperforms Market Similars in Weight Reduction Study

Fineline Cube Jun 25, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced the presentation of...

Company Drug

Novo Nordisk’s Once-Weekly Insulin Awiqli Approved by China’s NMPA for Type 2 Diabetes

Fineline Cube Jun 25, 2024

The National Medical Products Administration (NMPA) has granted market approval for Awiqli (insulin icodec), a...

Company Drug

Innovent Biologics’ Mazdutide Shows Promise in Phase III Obesity Trial

Fineline Cube Jun 25, 2024

Innovent Biologics Inc. (HKG: 1801), a biopharmaceutical company based in China, has announced the presentation...

Company Drug

Takeda’s Fruquintinib for Metastatic Colorectal Cancer Receives European Commission Marketing Approval

Fineline Cube Jun 24, 2024

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its partner Takeda (TYO: 4502,...

Company Deals

ClouDr Secures Exclusive Sub-Licensing Rights for Iloprost Infusion Solution

Fineline Cube Jun 24, 2024

Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), operating under the brand name “ClouDr,”...

Legal / IP

Biocytogen Secures US Patent for RenLite Fully Human Common Light Chain Mouse Platform

Fineline Cube Jun 24, 2024

Biocytogen (HKG: 2315), a biopharmaceutical company based in China, has announced that it has been...

Company Drug

ImmuneOnco Biopharmaceuticals Receives NMPA Approval for CD47 and CD20 Dual-Targeted BsAb in SLE

Fineline Cube Jun 24, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received clinical trial...

Company Deals

Shanghai Pharmaceuticals’ Subsidiary Shaphar Med Collaborates with Magic Med to Enter Oncology

Fineline Cube Jun 24, 2024

Shanghai Pharmaceuticals Holding Co., Ltd (SPH, SHA: 601607; HKG: 2607), a leading pharmaceutical company in...

Company Drug

Sichuan Biokin Pharmaceutical Gets NMPA Go-Ahead for BL-M17D1 Solid Tumor Clinical Study

Fineline Cube Jun 24, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced...

Company Drug

StarryGene Initiates Phase I Clinical Trial for XMVA09 Gene Therapy in wAMD

Fineline Cube Jun 24, 2024

StarryGene, a biotech company specializing in gene therapy and based in Hefei, China, has announced...

Company Drug

Gilead’s Lenacapavir Shows 100% Efficacy in Phase III HIV PrEP Study

Fineline Cube Jun 24, 2024

Gilead Sciences Inc. (NASDAQ: GILD), a U.S. biopharmaceutical company, has announced topline results from the...

Policy / Regulatory

Hefei Airport Port Designated as Drug Import Port by Chinese Authorities

Fineline Cube Jun 24, 2024

Hefei Airport Port, located in the city of Hefei, China, has been designated as a...

Company Drug

Zai Lab’s Partner Argenx Receives FDA Approval for CIDP Treatment Vygart Hytrulo

Fineline Cube Jun 24, 2024

Argenx SE (NASDAQ: ARGX), the U.S. partner of China-based biopharmaceutical company Zai Lab Ltd (NASDAQ:...

Company Deals

Inkon Life Technology Partners with United Imaging to Establish Advanced Medical Centers and Digital Platform

Fineline Cube Jun 24, 2024

Inkon Life Technology Co., Ltd. (SHE: 300143), a Shenzhen-based service provider specializing in stereotactic radiotherapy...

Company Deals

METiS Therapeutics Secures USD 100 Million in Series C Financing to Advance AI Drug Delivery

Fineline Cube Jun 24, 2024

METiS Therapeutics, a biopharmaceutical company based in Cambridge, Massachusetts, has secured USD 100 million in...

Posts pagination

1 … 367 368 369 … 692

Recent updates

  • Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory
  • Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million
  • LTZ Therapeutics Secures FDA IND Approval for LTZ-232, First-in-Class Myeloid Engager Targeting EpCAM-High Solid Tumors
  • Peking University Third Hospital Introduces World’s First PTH Replacement Therapy Palopegteriparatide Through Beijing Rare Disease Pilot Zone
  • MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Company Deals

Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million

Company Drug

LTZ Therapeutics Secures FDA IND Approval for LTZ-232, First-in-Class Myeloid Engager Targeting EpCAM-High Solid Tumors

Company Digital

Peking University Third Hospital Introduces World’s First PTH Replacement Therapy Palopegteriparatide Through Beijing Rare Disease Pilot Zone

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.